カテゴリ： GlobalData, アメリカ, 企業調査

Fortress Biotech Inc (FBIO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Fortress Biotech Inc (FBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9784
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：108
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Fortress Biotech Inc (Fortress), formerly Coronado Biosciences Inc is a biopharmaceutical company that develops and commercializes pharmaceutical and biotechnology products. The company offers products in the areas of dermatology, cancer, pain management and autoimmune diseases, among others. It offers Dermasorb HC, Luxamed wound cream and Ceracade. Fortress’s products are used to treat and manage atopic dermatitis, wounds and other dermatological diseases. The company also provides funding to support their research and development programs. It markets its products in the US and abroad. Fortress is headquartered in New York, the US.

Fortress Biotech Inc (FBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma 15
Venture Financing 16
Avenue Therapeutics Raises USD0.2 Million in Venture Financing 16
Helocyte Raises Additional USD2 Million in Venture Financing 17
Helocyte Raises USD1 Million in Venture Financing 18
Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 19
Partnerships 20
Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 20
Applied BioMath Enters into Agreement with Checkpoint Therapeutics 21
Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 22
Mustang Bio Enters into Agreement with Beth Israel Deaconess 23
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 24
Helocyte Enters into Agreement with City of Hope for PepVax 25
Helocyte Enters into Agreement with City of Hope 26
Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 27
Coronado Biosciences Forms Joint Venture with City of Hope 28
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 29
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 30
Licensing Agreements 31
Mustang Bio Enters into Licensing Agreement with St. Jude Children’s Research Hospital 31
Mustang Bio Enters into Licensing Agreement with Harvard University 32
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 33
Mustang Bio Enters into Licensing Agreement with City of Hope 34
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 35
Fortress Biotech Enters into Licensing Agreement with Columbia University 36
Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston 37
Fortress Biotech Enters into Licensing Agreement with Effcon Labs 38
Fortress Biotech Enters into Licensing Agreement with GeneMedicine 39
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 40
Journey Medical Enters into Licensing Agreement for Ceracade 41
Journey Medical Enters into Licensing Agreement for Luxamend 42
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 43
Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer 44
Mustang Bio Enters into Licensing Agreement with City of Hope 45
Helocyte Amends Agreement with City of Hope National Medical Center 46
Journey Medical Enters into Licensing Agreement for Dermatological Product 47
Fortress Biotech Amends its Licensing Agreement with NeuPharma 48
Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 49
Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome 51
Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol 52
Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis 53
Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201 54
Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application 56
Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO 58
Equity Offering 59
Mustang Bio Plans to Raise up to USD75 Million in Public Offering of Securities 59
Fortress Biotech Plans to Raise up to USD50 Million in Public Offering of Shares 60
Avenue Therapeutics Plans to Raise up to USD75 Million in Public Offering of Securities 61
Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 62
Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 64
Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million 65
Avenue Therapeutics Raises USD38 Million in IPO 67
Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 69
Mustang Bio Raises USD94.5 Million in Private Placement 70
Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units 71
Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units 72
Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 73
Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 74
Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares 75
Coronado Biosciences Files Registration Statement For Public Offering Of Securities For US$200 Million 76
Coronado Biosciences Announces Public Offering Of Common Stock For US$45 Million 77
Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For US$10 Million 78
Coronado Biosciences Completes Public Offering Of Shares For US$28.8 Million 79
Debt Offering 80
Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020 80
Fortress Biotech Inc – Key Competitors 81
Fortress Biotech Inc – Key Employees 82
Fortress Biotech Inc – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Joint Venture 84
Recent Developments 85
Financial Announcements 85
Nov 02, 2018: Checkpoint Therapeutics reports third quarter 2018 financial results and recent corporate highlights 85
Aug 09, 2018: Fortress Biotech reports second quarter 2018 financial results and recent corporate highlights 86
May 10, 2018: Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 88
Mar 16, 2018: Fortress Biotech Announces Fourth Quarter And Full-Year 2017 Financial Results 90
Nov 09, 2017: Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 93
Aug 14, 2017: Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 95
Aug 09, 2017: Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 96
May 10, 2017: Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights 98
Mar 16, 2017: Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016 100
Corporate Communications 103
Jul 03, 2017: Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics 103
Jul 03, 2017: Fortress Biotech names president and CEO of Avenue Therapeutics 104
Mar 14, 2017: Fortress Biotech Announces Appointment of Lung S. Yam, M.D., Ph.D., Named Cyprium Chief Executive Officer 105
Jan 04, 2017: Fortress Biotech announce the appointment of Michael Spector as Caelum’s Chief Executive Officer. 106
Appendix 107
Methodology 107
About GlobalData 107
Contact Us 107
Disclaimer 107

List of Tables
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Fortress Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma 16
Avenue Therapeutics Raises USD0.2 Million in Venture Financing 17
Helocyte Raises Additional USD2 Million in Venture Financing 18
Helocyte Raises USD1 Million in Venture Financing 19
Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 20
Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 21
Applied BioMath Enters into Agreement with Checkpoint Therapeutics 22
Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 23
Mustang Bio Enters into Agreement with Beth Israel Deaconess 24
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 25
Helocyte Enters into Agreement with City of Hope for PepVax 26
Helocyte Enters into Agreement with City of Hope 27
Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 28
Coronado Biosciences Forms Joint Venture with City of Hope 29
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 30
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 31
Mustang Bio Enters into Licensing Agreement with St. Jude Children’s Research Hospital 32
Mustang Bio Enters into Licensing Agreement with Harvard University 33
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 34
Mustang Bio Enters into Licensing Agreement with City of Hope 35
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 36
Fortress Biotech Enters into Licensing Agreement with Columbia University 37
Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston 38
Fortress Biotech Enters into Licensing Agreement with Effcon Labs 39
Fortress Biotech Enters into Licensing Agreement with GeneMedicine 40
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 41
Journey Medical Enters into Licensing Agreement for Ceracade 42
Journey Medical Enters into Licensing Agreement for Luxamend 43
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 44
Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer 45
Mustang Bio Enters into Licensing Agreement with City of Hope 46
Helocyte Amends Agreement with City of Hope National Medical Center 47
Journey Medical Enters into Licensing Agreement for Dermatological Product 48
Fortress Biotech Amends its Licensing Agreement with NeuPharma 49
Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 50
Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome 52
Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol 53
Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis 54
Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201 55
Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application 57
Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO 59
Mustang Bio Plans to Raise up to USD75 Million in Public Offering of Securities 60
Fortress Biotech Plans to Raise up to USD50 Million in Public Offering of Shares 61
Avenue Therapeutics Plans to Raise up to USD75 Million in Public Offering of Securities 62
Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 63
Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 65
Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million 66
Avenue Therapeutics Raises USD38 Million in IPO 68
Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 70
Mustang Bio Raises USD94.5 Million in Private Placement 71
Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units 72
Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units 73
Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 74
Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 75
Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares 76
Coronado Biosciences Files Registration Statement For Public Offering Of Securities For US$200 Million 77
Coronado Biosciences Announces Public Offering Of Common Stock For US$45 Million 78
Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For US$10 Million 79
Coronado Biosciences Completes Public Offering Of Shares For US$28.8 Million 80
Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020 81
Fortress Biotech Inc, Key Competitors 82
Fortress Biotech Inc, Key Employees 83
Fortress Biotech Inc, Other Locations 84
Fortress Biotech Inc, Subsidiaries 84
Fortress Biotech Inc, Joint Venture 85

List of Figures
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

★海外企業調査レポート[Fortress Biotech Inc (FBIO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Boston Scientific Corp (BSX)：企業の財務・戦略的SWOT分析
    Boston Scientific Corp (BSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • BlueWillow Biologics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary BlueWillow Biologics Inc (BlueWillow), formerly NanoBio Corp is a biopharmaceutical company that develops intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company’s pipeline products include anthrax, H5 influenza, pertussis, RSV, HSV-2, and s …
  • NTT Data Corporation：企業の戦略・SWOT・財務情報
    NTT Data Corporation - Strategy, SWOT and Corporate Finance Report Summary NTT Data Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pets at Home Group Plc：戦略・SWOT・企業財務分析
    Pets at Home Group Plc - Strategy, SWOT and Corporate Finance Report Summary Pets at Home Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JDC Group AG：企業のM&A・事業提携・投資動向
    JDC Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JDC Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Autotelic Inc-製薬・医療分野：企業M&A・提携分析
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products includes devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine and TGF-beta in …
  • Maxim Integrated Products Inc (MXIM)：企業の財務・戦略的SWOT分析
    Maxim Integrated Products Inc (MXIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The Hong Kong Jockey Club：企業の戦略的SWOT分析
    The Hong Kong Jockey Club - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sumitomo Corporation (8053)-エネルギー分野：企業M&A・提携分析
    Summary Sumitomo Corporation (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resourc …
  • AbCheck sro：製薬・医療：M&Aディール及び事業提携情報
    Summary AbCheck Sro (AbCheck), a subsidiary of Affimed NV is a healthcare technology company offers discovery and optimization of high-quality human antibodies. The company offers technology platforms such as Absieve, and AbAccel. Its Absieve is an antibody discovery technology that offers proprieta …
  • Sumitomo Corp (8053)：電力：M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • BioMarin Pharmaceutical Inc (BMRN)：製薬・医療：M&Aディール及び事業提携情報
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasi …
  • Kymab Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Kymab Ltd (Kymab) is a therapeutic antibody company that provides drug and vaccine development solutions. The company offers pipepline of assets in the therapeutic areas of immuno-oncology, inflammatory disease, haematology, and infectious diseases. Its pipeline products includes KY1003-Anti …
  • Electro Optic Systems Holdings Ltd (EOS)：企業の財務・戦略的SWOT分析
    Electro Optic Systems Holdings Ltd (EOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • CooperSurgical Inc-医療機器分野：企業M&A・提携分析
    Summary CooperSurgical Inc (CooperSurgical), a subsidiary of The Cooper Companies Inc is a medical device company that offers surgical instrument. The company offers surgical products, clinic and office products, labor and delivery products, and critical care products. Its surgical products include …
  • University of Pittsburgh Medical Center：企業の戦略的SWOT分析
    University of Pittsburgh Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Do & Co Poland Sp.Z.O.O
    Do & Co Poland Sp.Z.O.O - Strategy, SWOT and Corporate Finance Report Summary Do & Co Poland Sp.Z.O.O - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Michigan Public Power Agency：企業の発電所・SWOT分析2018
    Michigan Public Power Agency - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Genworth Financial, Inc.：企業の戦略・SWOT・財務情報
    Genworth Financial, Inc. - Strategy, SWOT and Corporate Finance Report Summary Genworth Financial, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gemalto N.V. (GTO)：企業の財務・戦略的SWOT分析
    Gemalto N.V. (GTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆